A Phase IV, Multicenter, Randomized, 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy of 2 Fixed Doses (50 and 100 mg/Day) of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder.

Trial Profile

A Phase IV, Multicenter, Randomized, 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy of 2 Fixed Doses (50 and 100 mg/Day) of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Oct 2014

At a glance

  • Drugs Desvenlafaxine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 24 Jan 2013 Results from this study will be submitted for presentation at upcoming scientific congresses and for publication in a peer-reviewed medical journal, according to a Pfizer media release.
    • 24 Jan 2013 Primary endpoint 'Hamilton-Depression-Rating-Scale' has been met.
    • 24 Jan 2013 Results published in a Pfizer media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top